Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments

Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety

NCT02818751 ·Status: COMPLETED ·Phase: NA

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

NCT03756129 ·Status: COMPLETED ·Phase: PHASE2

Psilocybin Versus Ketamine in Treatment-Resistant Depression

NCT05383313 ·Status: UNKNOWN ·Phase: PHASE2

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

NCT00035295 ·Status: COMPLETED ·Phase: PHASE3

Repeated Neurocognitive Measurements in Depressed Patients

NCT04916548 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

NCT04599855 ·Status: COMPLETED ·Phase: PHASE4

A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder

NCT02724735 ·Status: UNKNOWN

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111539 ·Status: TERMINATED ·Phase: PHASE3

Cognitive Training as an Adjunct to Ketamine in Real-world Clinics

NCT06526078 ·Status: ENROLLING_BY_INVITATION ·Phase: NA

Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders

NCT02411123 ·Status: COMPLETED ·Phase: NA

Treatment Response of Geriatric Depression

NCT00754936 ·Status: COMPLETED ·Phase: NA

Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)

NCT00610649 ·Status: COMPLETED ·Phase: PHASE2

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

NCT05973851 ·Status: RECRUITING ·Phase: PHASE3

Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication

NCT00375843 ·Status: COMPLETED ·Phase: PHASE4

Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant Depression

NCT04239963 ·Status: COMPLETED

Clinical Study of GH001 in Depression

NCT04698603 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Cognitive Behavioural Analysis System of Psychotherapy (CBASp) Versus Escitalopram in Chronic Depression

NCT00837564 ·Status: UNKNOWN ·Phase: PHASE3

A Study of Esketamine Nasal Spray Plus a New Standard-of-care Oral Antidepressant or Placebo Nasal Spray Plus a New Standard-of-care Oral Antidepressant in Adult and Elderly Participants With Treatment-resistant Depression

NCT03852160 ·Status: WITHDRAWN ·Phase: PHASE3

Treatments for Anxiety: Meditation and Escitalopram

NCT03522844 ·Status: COMPLETED ·Phase: PHASE4

Effects of Antidepressants on Sexual Functioning

NCT00051259 ·Status: COMPLETED ·Phase: PHASE3

Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)

NCT00750919 ·Status: TERMINATED ·Phase: PHASE3

Levomilnacipran in Healthy Males

NCT03249311 ·Status: UNKNOWN ·Phase: PHASE4

Ketamine + Mindfulness for Depression

NCT05168735 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

NCT06247839 ·Status: RECRUITING ·Phase: PHASE3

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-059)

NCT00035009 ·Status: COMPLETED ·Phase: PHASE3